X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CTX-009
Therapeutic Area: Oncology Product Name: TR009
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Compass Therapeutics
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 13, 2021
Details:
Compass Therapeutics obtains global rights to TR009, a novel bispecific antibody and inhibitor of the notch pathway targeting DLL4 and VEGF-A.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TR009
Therapeutic Area: Oncology Product Name: ABL001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Elpiscience
Deal Size: $117.0 million Upfront Cash: $7.0 million
Deal Type: Collaboration January 20, 2021
Details:
Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territory.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
